

September 16, 2024

The Manager, Listing Department  
The National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051  
NSE Symbol: PANACEABIO

BSE Limited  
Corporate Relationship Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400 001  
BSE Scrip Code: 531349

**Sub: Intimation of Disposal of suit filed by Panacea Biotec Limited (“Company”) against Sanofi Healthcare India Private Limited pursuant to settlement between the Parties**

**Reg.: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

This is with reference to our earlier letter dated May 17, 2021 wherein the Company has informed that it has instituted a suit before the Hon’ble Delhi High Court seeking to restrain Sanofi Healthcare India Private Limited (“Sanofi”) from marketing a fully liquid hexavalent vaccine that would infringe the Company’s patent for its wP-IPV based fully liquid hexavalent vaccine, EasySix®.

The aforesaid suit was filed against Sanofi after Sanofi received marketing approval for a Shan6, a whole cell Pertussis based hexavalent vaccine (DTwP-HepB-Hib-IPV) by the Drugs Controller General (India). When the suit was listed before the Hon’ble Delhi High Court, after elaborate submissions from both parties, Sanofi undertook that it would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351. A brief note on EasySix® vaccine is annexed herewith as **Annexure A**.

We are pleased to inform you that the parties have reached a settlement agreement, and pursuant to the joint application filed by the Parties, the said suit has been disposed of by the Hon’ble Delhi High Court on September 13, 2024, in terms of the settlement agreement entered between the Parties.

A copy of the said Order is received by the Company today i.e. September 16, 2024 at 07:31 p.m. (IST).

Under the terms of settlement agreement, Sanofi has inter-alia, agreed that at present **Sanofi would not directly or indirectly commercially launch its fully liquid hexavalent vaccine Shan6 in India** and shall also withdraw the Opposition under Section 25(2) and Opposition under Section 57(3) against amendment application filed against Panacea Biotec’s Patent IN 272351 on hexavalent vaccine before the Indian Patent Office. The aforesaid, in the interest of complete disclosure, is without prejudice to the rights and contentions of both parties, should Panacea Biotec subsequently decide to revive the suit proceedings in the event the circumstances so demand. Panacea Biotec has also agreed to forego its claim for damages and rendition of accounts in the proceedings against Sanofi as prayed for in the suit.

**Panacea Biotec Limited (CIN: L33117PB1984PLC022350)**

**Registered Office : Ambala-Chandigarh Highway, Lalru – 140501, Punjab**

Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India  
Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9015 Email: corporate@panaceabiotec.com

EasySix<sup>®</sup> is the first innovative fully-liquid hexavalent vaccine from India which is protected by patents in several countries including India. A first of its kind lawsuit wherein an Indian company in vaccine industry has asserted violation of its registered patent. The Patent IN272351 in favour of Panacea Biotec is also a testament to our ability to innovate and to protect that innovation.

The details of the said settlement in the specified format as per the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is annexed herewith as **Annexure B**.

This is for your kind information and record please.

Thanking you,

Sincerely yours,

For **Panacea Biotec Limited**

**Vinod Goel**

Group CFO and Head Legal  
& Company Secretary

## Annexure A

### Brief Note on EasySix<sup>®</sup> Vaccine

Panacea Biotec has developed the world's first whole-cell pertussis (wP) and inactivated polio vaccine (IPV) based fully liquid hexavalent vaccine, called EasySix<sup>®</sup> and is used to vaccinate against Diphtheria, Tetanus, Whooping Cough, Hepatitis B, *Haemophilus influenza* type b and Inactivated Polio (DTwP-HepB-Hib-IPV). The Company has launched this vaccine in India in March 2017 and, as Panacea Biotec expects, will be made available in government vaccination / immunization programmes, both domestically and internationally. Panacea Biotec has made available over 200 million doses of fully liquid combination vaccines across the world, e.g., Easyfive<sup>®</sup>-TT (DTwP-HepB-Hib), EasyFour<sup>®</sup>-TT (DTwP-Hib), IPV-based tetravalent vaccine – EasyFour<sup>®</sup>-Pol (DTwP-IPV) and bivalent oral polio vaccine (type-1 and type-3).

The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines, which will lead to less vaccination sessions and higher coverage. In October 2021, World Health Organization and Strategic Advisory Group of Experts on Immunization approved adoption of this hexavalent vaccine in the global immunization program. Following this, Gavi and the Pan American Health Organization also adopted the hexavalent vaccine in June 2023 and May 2023 respectively. UNICEF forecasts the demand for a wP-IPV-based hexavalent vaccine for Gavi countries to be 19 million doses in 2025 and over 100 million doses by 2030. This is an exceptionally impactful project for DFC given Panacea's worldwide reach and potential to save millions of lives.

Panacea Biotec is expanding manufacturing capacity for drug substance antigens used in its hexavalent vaccine EasySix<sup>®</sup> to meet future demand from U.N. agencies and public health organizations. The U.S. Government's development finance institution, the U.S. International Development Finance Corporation (DFC) has recently agreed to provide a long-term loan of upto US\$ 20 million to Panacea Biotec to help finance this project. DFC and Panacea Biotec signed a commitment letter for this financing on September 12, 2024. DFC's financing will enable Panacea Biotec to expedite completion of the ongoing expansion and supply the hexavalent vaccine to U.N. agencies for childhood immunization globally.

The battle for Whole Cell Pertussis based vaccines has several aspects and considerations in the global market. Currently, there are two types of pertussis vaccines licensed for use: whole cell pertussis (wP) and acellular pertussis (aP). Immunization with wP vaccines has been deemed as comparably effective and relatively inexpensive. Although aP vaccines have gradually supplanted the use of wP vaccines in industrialized countries, the significantly higher development and production costs of aP vaccines result in prices that are much higher than that of a dose of wP vaccine. Since the relative protective efficacy of the best wP and aP vaccines appear comparable and the adverse events of both vaccines are relatively minor, wP vaccines remain the vaccine of choice in many developing countries.

**Panacea Biotec Limited (CIN: L33117PB1984PLC022350)**

**Registered Office : Ambala-Chandigarh Highway, Lalru – 140501, Punjab**

Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India  
Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9015 Email: corporate@panaceabiotec.com

**Annexure B**

**Details required under Clause B(8) of Annexure I of the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023**

#	Particulars	Details
1.	Name of the Authority	Hon'ble Delhi High Court
2.	The details of any change in the status and / or any development in relation to such proceedings	The Parties have filed with the Hon'ble Delhi High Court, a joint application for settlement of the suit for Patent infringement filed earlier by the Company against Sanofi Healthcare India Private Limited, and the matter has been disposed of by the Hon'ble Delhi High Court on September 13, 2024.
3.	In the case of litigation against key management personnel or its promoter or ultimate person in control, regularly provide details of any change in the status and / or any development in relation to such proceedings	Not Applicable
4.	In the event of settlement of the proceedings, details of such settlement including - terms of the settlement, compensation/ penalty paid (if any) and impact of such settlement on the financial position of the listed entity	<p>Pursuant to the settlement, it has, inter-alia, been agreed between the Parties that:</p> <p>a) Sanofi would not be at present directly or indirectly commercially launching the fully liquid hexavalent vaccine Shan6 in India;</p> <p>b) Sanofi shall withdraw the oppositions filed by it against Panacea Biotec's Patent on hexavalent vaccine, the Post Grant opposition as well as the opposition to the amendment thereof and shall file the necessary applications before the Indian Patent Office in this regard; and</p> <p>c) Panacea Biotec shall forego its claim for damages and rendition of accounts in the proceedings as regards Sanofi, as prayed for in the suit.</p> <p>There is no impact of such settlement on the financial position of the Company.</p>

**Panacea Biotec Limited (CIN: L33117PB1984PLC022350)**

**Registered Office : Ambala-Chandigarh Highway, Lalru – 140501, Punjab**

Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India

Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9015 Email: corporate@panaceabiotec.com